全文获取类型
收费全文 | 147篇 |
免费 | 8篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 2篇 |
基础医学 | 7篇 |
口腔科学 | 5篇 |
临床医学 | 15篇 |
内科学 | 59篇 |
神经病学 | 8篇 |
特种医学 | 11篇 |
外科学 | 16篇 |
综合类 | 3篇 |
一般理论 | 1篇 |
预防医学 | 14篇 |
药学 | 5篇 |
肿瘤学 | 8篇 |
出版年
2022年 | 1篇 |
2020年 | 2篇 |
2019年 | 5篇 |
2018年 | 7篇 |
2017年 | 3篇 |
2016年 | 1篇 |
2015年 | 2篇 |
2014年 | 4篇 |
2013年 | 4篇 |
2012年 | 8篇 |
2011年 | 22篇 |
2010年 | 6篇 |
2009年 | 9篇 |
2008年 | 18篇 |
2007年 | 10篇 |
2006年 | 12篇 |
2005年 | 7篇 |
2004年 | 5篇 |
2003年 | 6篇 |
2002年 | 7篇 |
2001年 | 1篇 |
1999年 | 2篇 |
1998年 | 3篇 |
1996年 | 1篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1982年 | 1篇 |
1980年 | 3篇 |
1979年 | 1篇 |
1976年 | 1篇 |
排序方式: 共有156条查询结果,搜索用时 31 毫秒
21.
22.
23.
24.
25.
Jose Velasco Jaspal Singh Paravasthu Ramanujam Michael Friedberg 《European journal of nuclear medicine and molecular imaging》1982,7(1):11-13
To validate the use of 99mTc-PIPIDA in the diagnosis of biliary tract disease, 117 patients with clinical symptoms of acute cholecystitis were prospectively scanned as an initial screening test. The accuracy of the test was evaluated on the basis of surgical pathology in 59 patients. Three groups were defined: cystic duct obstruction, common duct obstruction, and normal scan. The diagnostic accuracy of the test for acute cholecystitis was 97%. Complete common duct obstruction was confirmed at surgery in 12 patients (100%). A normal scan helped to rule out acute cholecystitis. Jaundice did not influence the reliability of the method. Hepatobiliary scanning is an accurate, safe, and rapid diagnostic test for acute cholecystitis. 相似文献
26.
27.
28.
Pulmonary infection due to Blastoschizomyces capitatus is less common. It is an emerging fungal pathogen. We describe a case of Blastoschizomyces capitatus pneumonia in an otherwise healthy female and review the clinical presentation, microbiological characteristics, and treatment for B. capitatus infection. 相似文献
29.
30.
Marin D Milojkovic D Olavarria E Khorashad JS de Lavallade H Reid AG Foroni L Rezvani K Bua M Dazzi F Pavlu J Klammer M Kaeda JS Goldman JM Apperley JF 《Blood》2008,112(12):4437-4444
The majority of patients with chronic myeloid leukemia in chronic phase gain substantial benefit from imatinib but some fail to respond or lose their initial response. In 2006, the European LeukemiaNet published recommendations designed to help identify patients responding poorly to imatinib. Patients were evaluated at 3, 6, 12, and 18 months and some were classified as "failure" or "suboptimal responders." We analyzed outcomes for 224 patients with chronic myeloid leukemia in chronic phase treated in a single institution to validate these recommendations. Patients were followed for a median of 46.1 months. At each time point, patients classified as "failure" showed significantly worse survival, progression-free survival, and cytogenetic response than other patients; for example, based on the assessment at 12 months, the 5-year survival was 87.1% versus 95.1% (P = .02), progression-free survival 76.% versus 90% (P = .002), and complete cytogenetic response rate 26.7% versus 94.1% (P < .001). Similarly, the criteria for "suboptimal response" at 6 and 12 months identified patients destined to fare badly, although criteria at 18 months were less useful. The predictive value of some other individual criteria varied. In general, the LeukemiaNet criteria have useful predictive value, but a case could now be made for combining the categories "failure" and "suboptimal response." 相似文献